Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Chen

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2022
An anti-CTLA-4 heavy chain-only antibody with enhanced T<sub>reg</sub> depletion shows excellent preclinical efficacy and safety profileXin Gan, Qianqian Shan, He Li, et al.
Scientific Reports|May 19, 2023
YB1 modulates the DNA damage response in medulloblastomaLeon F McSwain, Claire E Pillsbury, Ramona Haji-Seyed-Javadi, et al.
Contemporary Clinical Trials Communications|August 6, 2024
Redefining feasibility in clinical trials: Collaborative approaches for improved site selectionBeau Bruneau, Kristin Surdam, Amy Bland, et al.
Scientific Reports|June 15, 2023
Author Correction: YB1 modulates the DNA damage response in medulloblastomaLeon F McSwain, Claire E Pillsbury, Ramona Haji-Seyed-Javadi, et al.
Open Forum Infectious Diseases|August 30, 2021
Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York CityKelsie Cowman, Yi Guo, Liise-Anne Pirofski, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2022
An anti-CTLA-4 heavy chain-only antibody with enhanced T<sub>reg</sub> depletion shows excellent preclinical efficacy and safety profileXin Gan, Qianqian Shan, He Li, et al.
Scientific Reports|May 19, 2023
YB1 modulates the DNA damage response in medulloblastomaLeon F McSwain, Claire E Pillsbury, Ramona Haji-Seyed-Javadi, et al.
Contemporary Clinical Trials Communications|August 6, 2024
Redefining feasibility in clinical trials: Collaborative approaches for improved site selectionBeau Bruneau, Kristin Surdam, Amy Bland, et al.
Scientific Reports|June 15, 2023
Author Correction: YB1 modulates the DNA damage response in medulloblastomaLeon F McSwain, Claire E Pillsbury, Ramona Haji-Seyed-Javadi, et al.
Open Forum Infectious Diseases|August 30, 2021
Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York CityKelsie Cowman, Yi Guo, Liise-Anne Pirofski, et al.
Pageof 6